

Reimbursement and clinic reference guide

Barostim Patient Flow

Patient identification · ICD consult HF hospitalization · HF diagnostic alert · EMR screening Patient assessment · Symptomatic despite GDMT • Recent echo (LVEF ≤ 35%) Baseline NT-proBNP (< 1600 pg/mL) May require medical optimization and re-test · Consider carotid doppler Prior authorization · CVRx Patient Access Support · Submit required documentation (NYHA class, EKG, Echocardiogram, NT-proBNP) Pre-implant consultation · Confirm carotid doppler (< 50% stenosis & anatomy) **Implant** · CVRx rep attendance · Consider device rep attendance for other implanted devices Wound check • Implant + 1 week Titration phase · CVRx rep attendance Typically three titration visits (1/month) • Depending on the patient, the titration phase can extend through 3-6 months Routine follow-up · Every 6 months

Vascular SurgeonCT SurgeonElectrophysiologist

Cardiologist HF Specialist Electrophysiologist

Patient assessment

Barostim indications¹

- NYHA III or NYHA II (with recent NYHA III) despite treatment with GDMT* (medications and devices)
- O LVEF ≤ 35%
- NT-proBNP < 1600 pg/mL</p>

Barostim delivers Baroreflex Activation Therapy for improvement of patients' heart failure functional status, six-minute hall walk, and quality of life.

Contraindications

- · Been assessed to have bilateral carotid bifurcations located above the level of the mandible
- · Baroreflex failure or autonomic neuropathy
- · Uncontrolled, symptomatic cardiac bradyarrhythmias
- Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50%
- Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
- Known allergy to silicone or titanium

NOTE: Boston Scientific's S-ICD and Medtronic's EV-ICD contraindicates patients with unipolar pacing devices (e.g.: Barostim, which uses unipolar stimulation)

^{*}Guideline directed medical therapy (GDMT) according to 2022 AHA/ACC/ESC guidelines

Prior authorization

Barostim requires prior authorization approvals based on the patient medical necessity criteria.

CVRx offers Prior Authorization support.

CVRx Prior Authorization support provides case-by-case support for providers who perform Barostim implantation procedures.

It is a HIPAA compliant entity and offers assistance for the following services:

- 1. Coding and coverage information
- 2. Eligibility and benefit verification
- 3. Prior authorization
- 4. Pre-determination or certification
- 5. Pre and post service appeals

To enroll in the CVRx Prior Authorization support service or submit a request online:

www.cvrx.com/healthcare-professionals/reimbursement

Contact the CVRx helpline for copies of the forms or with any questions:

Email: reimbursement@cvrx.com

Phone: 763-416-2344 Fax: 855-710-7053

Follow-up

Routine follow-up phase

Once a patient has completed their titration phase, they enter into the routine follow-up phase.

Timing

- Every six months patients should return to their doctor's office for a check of the battery status and lead impedance.
- The Barostim therapy generator is designed to have an average battery life of 5 years with no charging required.

Unscheduled or urgent device checks

- Unlike pacemakers or ICDs, Barostim is not providing beat-to-beat life supporting therapy and a malfunction should not be life threatening.
- However, on rare occasions if the patient is experiencing stimulation in the neck, the therapy can be suspended
 with a magnet. Therapy will remain off as long as the magnet is in place. Therapy adjustments can then be made
 when programming is convenient.

CVRx field representatives are available to support device follow-ups and to train staff to perform routine device status checks.

Technical support (24/7) Phone: 763-416-2343

Contact CVRx with any questions:

Email: reimbursement@cvrx.com

Phone: 763-416-2344

System implant - Commonly used diagnosis codes*

ICD-10-CM ²	Descriptor
150.2	Systolic (Congestive) Heart Failure
150.20	Unspecified Systolic (Congestive) Heart Failure
I50.21	Acute Systolic (Congestive) Heart Failure
150.22	Chronic Systolic (Congestive) Heart Failure
150.23	Acute on Chronic Systolic (Congestive) Heart Failure
150.3	Diastolic (Congestive) Heart Failure
150.30	Unspecified Diastolic (Congestive) Heart Failure
I50.31	Acute Diastolic (Congestive) Heart Failure
150.32	Chronic Diastolic (Congestive) Heart Failure
150.33	Acute on Chronic Diastolic (Congestive) Heart Failure
150.4	Combined Systolic (Congestive) and Diastolic (Congestive) Heart Failure
150.40	Unspecified Combined Systolic (Congestive) and Diastolic (Congestive) Heart Failure
I50.41	Acute Combined Systolic (Congestive) and Diastolic (Congestive) Heart Failure
150.42	Chronic Combined Systolic (Congestive) and Diastolic (Congestive) Heart Failure
150.43	Acute on Chronic Combined Systolic (Congestive) and Diastolic (Congestive) Heart Failure

^{*}Not a complete list

System implant - physician billing

Physician system implant code (this code is used for billing)


CPT® code³	Descriptor
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system

Barostim system implant is reported with a Category III CPT® code. When submitting codes, providers may choose to reference a comparative Category I CPT® procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

Example Comparative codes (these codes are examples, they are not billed)

Comparative code	Descriptor	Work RVU⁵
64568	Open implantation of cranial nerve (eg: vagus nerve) neurostimulator electrode array and pulse generator	9
64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array	14

System implant physician billing sample



System implant

For an initial "system implant" (full device – Generator and Lead at the same time) use the following product numbers:

• 100069-202, Barostim Neo2 Neurostimulator System IPG Model CSL Comb Kit

This procedure is always billed using **C1825** - Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s).

Any (single part below) **replacements** are billed using **C1767** (Generator) and **C1778** (Lead) – see crosswalk below and more on page 16 under Replacement

100065-202, Barostim NEO2 Model 2104 (**IPG** only) 100063-212, Barostim Neo CSL Kit Model 1036 SH (**lead** only)

Procedure	Descriptor	CPT® code ³	HCPCS code ⁴	Item #
Initial Barostim System Implant (Kit) De novo implant only	Implantation or replacement of carotid sinus baroreflex activation device; total system	0266T	C1825	100069-202, Barostim Neo2 Neurostimulator System IPG Model CSL Comb Kit
Battery replacement only (Barostim)	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only	0268T	C1767	100065-202, Barostim NEO2 Model 2104 IPG (only)
Lead replacement only	Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral	0267T	C1778	100063-212, Barostim Neo CSL Kit Model 1036 SH (lead only)

Contact the CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

System implant - outpatient hospital billing4


CPT® code³	Descriptor	Status indicator	APC ⁶
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system	S	1580

S - Procedure or Service, Not Discounted When Multiple. Paid under OPPS; separate APC payment.

HCPCS code⁴	Descriptor	APC ⁶
C1825	Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)	2030

Contact the CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

Outpatient UB-04 sample




System implant - inpatient hospital billing6

ICD-10-PCS procedure code ²	Descriptor	Typical MS-DRG assignment ⁷
0JH60MZ	Insertion of stimulator generator into chest	
0011001112	subcutaneous tissue and fascia, open approach	276
AND		
03HK3MZ	Insertion of stimulator lead into right internal carotid	Cardiac Defibrillator
551 H5W2	artery, percutaneous approach	Implant with MCC
<u>OR</u>		or Carotid Sinus
03HL3MZ	Insertion of stimulator lead into left internal carotid artery, percutaneous approach	Neurostimulator

Contact CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

Inpatient UB-04 sample



Follow-up - physician billing

Possible **primary diagnosis** codes for interrogation and programming. Possible **secondary diagnosis** codes for interrogation and programming are Heart Failure diagnosis codes (see page 6)

Code ²	Descriptor
Z45.09	Encounter for adjustment and management of other cardiac device
Z45.89	Encounter for adjustment and management of other implanted devices

Follow up visits or services may be billed independently from the Barostim device interrogation (with or without programming) and evaluation visits.

Part 1 Physician billing: follow up visit CPT® codes

Category III CPT® codes are not assigned global periods, so any subsequent visits or services may be billed independently from the initial procedure. The following E/M CPT® codes may be used to report follow-up visits. If device interrogation/programming is also performed, the -25 modifier may be added to the E/M code to indicate that it is a separate service.

CPT® code³	
99211	Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a physician or other qualified health care professional.
99212	Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making. When using total time on the date of the encounter for code selection, 10 minutes must be met or exceeded.
99213	Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making. When using total time on the date of the encounter for code selection, 20 minutes must be met or exceeded.
99214	Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making. When using total time on the date of the encounter for code selection, 30 minutes must be met or exceeded.
99215	Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making. When using total time on the date of the encounter for code selection, 40 minutes must be met or exceeded.

Follow-up - physician coding and billing (continued)

Part 2 Physician billing: follow-up visit device interrogation with programming³

Whenever programming is performed, it is essential that physicians individually document the specific parameters changed for coding purposes. Barostim device interrogation is reported with Category III CPT® codes. When submitting claim information, providers may choose to reference a comparative Category I CPT® procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

This code is used for billing:

CPT® 0273T - Interrogation device evaluation with programming

Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report; with programming

Example Comparative codes (these codes are examples, they are not billed):

CPT® Code³	Descriptor	RVU⁵
93284	multiple lead transvenous implantable defibrillator system	3.12 T 1.25W
93281	multiple lead pacemaker system	2.47 T .85 W
93282	single lead transvenous implantable defibrillator system	2.35 T .85 W

This code is used for billing:


CPT® 0272T – Interrogation device evaluation

Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day)

Example Comparative codes (these codes are examples, they are not billed):

CPT® Code³	Descriptor	RVU⁵
93289	single, dual, or multiple lead transvenous implantable defibrillator system, including analysis of heart rhythm derived data elements	2.12 T .75 W
93261	implantable subcutaneous lead defibrillator system	2.08 T .74 W
93288	single, dual, or multiple lead pacemaker system, or leadless pacemaker system	1.66 T .43 W

Follow up and device titration physician billing sample



Generator replacement - physician billing

Physician generator replacement code (this code is used for billing)


CPT® code³	Descriptor
Battery replace	ment
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)

Barostim generator replacement is reported with Category III CPT® codes. When submitting claim information, providers may choose to reference a comparative Category I CPT® procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

Example Comparative codes (these codes are examples, they are not billed)

Comparative	e code	Work RVU⁵
61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array	6.05

Generator replacement physician billing sample



Generator replacement - outpatient hospital billing

CPT® code³	Descriptor	Status indicator	APC ⁶	
Battery replace	ement			
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5465	

HCPCS level II device codes

The following HCPCS Level II codes should be used for cost reporting purposes when reporting Barostim generator replacement. In general, C-codes are used for billing Medicare and L-codes are used for billing private payers, although some private payers may also accept C-codes.

HCPCS code⁴	Descriptor
Battery and lea	ad replacement
C1767	Generator, neurostimulator (implantable), non-rechargeable
C1778	Lead, neurostimulator (implantable)
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
L8680	Implantable neurostimulator electrode, each

Generator replacement outpatient UB-04 sample

31 OCCU CODE	JRRENCE DATE	32 O	CCURRENCE	33 C	DCCURRENCE DATE	34 CODE	OCCURRENCE DATE	35 CODE		CCURRENCE	SPAN THROUGH	36 CODE	OCCURRENC FROM		THROUGH	37		
																		-
38								Т	39 CODE	VALUE CO AMOL	DDES INT	40 CODE	VALUE CODES AMOUNT		41 CODE	VALUE CODES AMOUNT		П
								а						:			:	7
PATIENT								b									- :	ı
PATIENT	ADDRESS							С										
								d									:	
42 REV. CD.	43 DESCRIPTION	ı				44 HCPC	S / RATE / HIPPS CODE	•	45	SERV. DATE	46 SERV. UNIT	'S	47 TOTAL CHARGES	•	48 NON-C	OVERED CHARGES	49	
0130	EKG										#		\$XXXXX	XX		:		
0250	PHARMACY										#		\$XXXX	XX				
0258	IV SOLUTION	1									#		\$XXXXX	XX				
0270	MEDICAL / SI	URGICA	L SUPPLIES								#		\$XXXXX	XX				
0278	OTHER DEVI	CE / IMF	PLANT				C1767			01012025	1		\$XXXXX	XX				
0360	OPERATING	ROOM					0268T			01012025	1		\$XXXXX	XX		:		
0370	ANESTHESIA	4									#		\$XXXX	XX				
0710	RECOVERY I	ROOM									#		\$XXXXX	XX				
																		_

Ambulatory surgery center

Procedures involving the Barostim System may be also performed in the Ambulatory Surgery Centers (ASC). The following CPT® codes may be used as a guide for Ambulatory Surgery Center (ASC) reporting.

CPT® code³	Descriptor	ASC ⁶ payment indicator
Insertion/Re	placement	
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	J8
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	J8
Revision/Rei	moval	
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	G2
0270T	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	G2
0271T	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	G2

J8 – Device intensive procedure, paid at adjusted rate

G2 - Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight

Reimbursement appendix⁴

CPT® code³	Descriptor	Status indicator	APC ⁶
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system	S	1580
0267T	Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5461
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5465
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Q2	5432
0270T	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5461
0271T	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5461
0272Т	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day)	S	5721
0273T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report; with programming	S	5721

Hospital Outpatient Status Indicator:

J1- Hospital Part B services paid through a Comprehensive APC (C-APC). Comprehensive APCs (C-APCs) were established for certain payment groups (e.g., device intensive) whereby Medicare only reimburses a single C-APC on a date of service.

Q2- Paid under OPPS; Addendum B displays APC assignments when services are separately payable.

S- Procedure or Service, Not Discounted When Multiple; *Medicare rate for 2025

CVRx contacts

Contact

Technical support (24/7) Phone: 763-416-2343

Reimbursement

Phone: 763-416-2344 Fax: 855-710-7053

Email: reimbursement@cvrx.com

Prior authorization

Email: c-pas@cvrx.com

www.cvrx.com/reimbursement

Local Team	
Sales	
Clinical support	
Training	

Reimbursement

Reimbursement information provided by CVRx is gathered from 3rd party sources and is presented for illustrative purposes only. This information does not constitute legal or reimbursement advice. CVRx makes no representation or warranty regarding this information or its completeness, accuracy, timeliness or applicability with any particular patient. CVRx specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this document. CVRx encourages providers to submit accurate and appropriate claims for services. Laws, regulations and payer policies concerning reimbursement are complex and change frequently. Providers are responsible for making appropriate decisions related to coding and reimbursement submissions. Accordingly, CVRx recommends that customers consult with their payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters.

References:

- 1. Instructions for Use 900133-001 Rev. E available at www.cvrx.com/ifu
- 2. ICD-10-PCS and ICD-10-CM 2024, American Medical Association, Chicago, IL.
- 3. Current Procedural Terminology 2024, American Medical Association. Chicago, IL. CPT is a registered trademark of the American Medical Association. Current Procedural Terminology (CPT®) is copyright American Medical Association. All Rights Reserved. Applicable FARS/ DFARS apply.
- 4. Source: Optum360 EncoderProForPayers.com
- 5. 2025 Physician Final Rule CMS -1807.
- 6. 2025 OPPS and ASC Final Rule CMS 1809-FC.
- 7. 2025 IPPS Final Rule CMS-1808-F.

CAUTION: Federal law restricts this device to sale by or on the order of a physician. See Instructions for Use 900133-001 for a complete instruction for use and a description of indications, contraindications, warnings, precautions and adverse events.

Barostim is indicated for patients who are NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed medical therapies (medications and devices), have a left ventricular ejection fraction of \leq 35%, and a NT-proBNP <1600 pg/ml. Barostim delivers Baroreflex Activation Therapy for improvement of patients' heart failure functional status, six-minute hall walk, and quality of life.

Patients are contraindicated if they have been assessed to have bilateral carotid bifurcations located above the level of the mandible, baroreflex failure or autonomic neuropathy, uncontrolled symptomatic cardiac bradyarrhythmias, carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50%, ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation, known allergy to silicone or titanium.

Warnings include: only trained physicians may use this system, prescribing physicians should be experienced in the diagnosis and treatment of heart failure and should be familiar with the use of this system, monitor blood pressure and heart rate during Carotid Sinus Lead placement and when adjusting stimulation parameters intra-operatively, post-implantation, program the system to avoid the following: heart rate falls below 50 beats per minute (BPM), or systolic pressure falls below 90 mmHg, or distolic blood pressure falls below 50 mmHg, or problematic adjacent tissue stimulation is noted, or undesirable interaction indicated by monitoring of any other implanted electrical device (see "Device Interaction Testing" in Section 10), or any other potentially hazardous patient responses are observed. Improper system implantation could result in serious injury or death. Do not use diathermy therapy including shortwave, microwave, or therapeutic ultrasound diathermy on patients implanted with the system. Patients should be counseled to stay at least 15 cm (6 inches) away from devices with strong electrical or magnetic fields such as strong magnets, loudspeaker magnets, Electronic Article Surveillance (EAS) system tag deactivators, arc welders, induction furnaces, and other similar electrical or electromechanical devices. This would include not placing items such as earphones in close proximity to the implanted pulse generator. The IPG may affect the operation of other implanted devices such as cardiac defibrillators, pacemakers, or neurological stimulation systems. For patients who currently have an implanted electrical medical device, physicians must verify compatibility with the implanted device during implantation of the system. Contralateral implant of the Barostim NEO IPG may help to reduce potential interactions. Interactions are more likely in devices that contain a sensing function, such as an implantable cardiac defibrillator or pacemaker. If an interaction is observed, the Barostim NEO IPG should be programm

Precautions include: the system should be implanted and programmed carefully to avoid stimulation of tissues near the electrode or in the area of the IPG pocket. Such extraneous stimulation could involve the following: the regional nerves, causing laryngeal irritation, difficulty swallowing, or dyspnea, the cervical musculature, causing intermittent contraction, skeletal muscles, causing intermittent contraction around the IPG pocket. Proper sterile technique during implantation should be practiced and aggressive pre-operative antibiotics are recommended. Infections related to any implanted device are difficult to treat and may necessitate device explantation.

It is anticipated that subjects will be exposed to operative and post-operative risks similar to related surgical procedures involving the neck and/or a pacemaker implant. These risks and potential risks of chronic device based baroreflex activation may include, but are not limited to: stroke, transient ischemic attack (TIA), systemic embolization, surgical or anesthetic complications, infection, wound complications, arterial damage, pain, nerve damage/stimulation, hypotension, hypotension, hypotension, exacerbation of heart failure, cardiac arrhythmias, tissue erosion/IPG migration, injury to baroreceptors, fibrosis, allergic reaction, general injury to user or patient, need for reoperation, secondary operative procedure, and death. Patients implanted with the system may receive Magnetic Resonance Imaging (MRI) only when all MR Conditional safety parameters are met as listed in the instructions for use.

CVRx, Barostim, Barostim NEO, Barostim NEO2, BATwire, "Outsmart the heart" and Barohub are all trademarks of CVRx, Inc. ©2025 CVRx, Inc. All rights reserved. All other trademarks are property of their respective owners.

For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/ For a list of all applicable patents, see www.cvrx.com/patent-marking.

CVRx, Inc. 9201 West Broadway Ave., Suite 650 Minneapolis, MN 55445 Phone: (763) 416-2840 Fax: (763) 416-2841

www.cvrx.com

PRO-1027-US-ENG-v2

